Back to search
FDAFDA · Food and drugs·Recall number D-1218-2014

Bupivacaine 3%, 300 mL units, Not for Dispensing, For Hospital Administration Only, Rx Formulations, 5949 East University Drive, Mesa, AZ 85205

Published April 16, 2014 · Recall initiated: December 12, 2013

Summary

FDA records drug Class II recall D-1218-2014, published April 16, 2014 and initiated December 12, 2013. Recalling firm: Zions RX Formulations Services LLC dba RX Formuations Serv.; Status: Terminated; Reported quantity: 60 units; Lot: Lot #: 117456@3 Expiration Date: 12/12/2013 Lot #: 117907@3 Expiration Date: 12/19/2013 Lot #: 118297@8 Expiration Date: 12/25/2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Zions RX Formulations Services LLC dba RX Formuations Serv.
Distributor
AZ
Lot
Lot #: 117456@3 Expiration Date: 12/12/2013 Lot #: 117907@3 Expiration Date: 12/19/2013 Lot #: 118297@8 Expiration Date: 12/25/2013
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Bupivacaine 3%, 300 mL units, Not for Dispensing, For Hospital Administration Only, Rx Formulations, 5949 East University Drive, Mesa, AZ 85205 recalled?

Yes. FDA published recall D-1218-2014 on April 16, 2014. Reported hazard: Lack of Assurance of Sterility: The firm expanded the recall to other injectable products due to lack of assurance of sterility from poor aseptic practices observed at the firm.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail